Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia

Title
Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia
Author(s)
김민경이상민[이상민]주영돈[주영돈]신호진[신호진]이제중[이제중]손상균[손상균]문준호[문준호]엄현석[엄현석]원종호[원종호]이규형[이규형]이제환[이제환]김대영[김대영]윤성수[윤성수]김인호[김인호]정철원[정철원]김석진[김석진]김혁[김혁]이재훈[이재훈]류헌모[류헌모]김성현[김성현]문영철[문영철]이원식[이원식]이경원[이경원]
Keywords
ACUTE LYMPHOCYTIC-LEUKEMIA; DOSE-INTENSIVE REGIMEN; TERM-FOLLOW-UP; HYPER-CVAD; THERAPY; CYCLOPHOSPHAMIDE; CLASSIFICATION; VINCRISTINE; DOXORUBICIN; PROPOSALS
Issue Date
201308
Publisher
SPRINGER
Citation
ANNALS OF HEMATOLOGY, v.92, no.8, pp.1101 - 1110
Abstract
The dose intensity of daunorubicin (DNR) delivered during the induction period represented the major prognostic factor for the outcome of adult acute lymphoblastic leukemia (ALL). The aim of this study was to determine the survival or toxicity of escalated doses of DNR in induction treatment of adult patients with acute lymphoblastic leukemia who are at least 15 years of age. For induction chemotherapy, all patients were given 90 mg/m(2)/day of DNR by continuous intravenous (IV) infusion over 24 h daily on days 1-3, 2 mg of vincristine IV push on days 1 and 8, and 60 mg/m(2)/day of prednisolone per oral (PO) on days 1-14 in conjunction with 4,000 units/m(2)/day of l-asparaginase intramuscular or subcutaneous on days 17-28. The median patient age was 32 years (range, 15-69). Complete remission (CR) was achieved in 169 (88.5 %) patients, while 4 died before CR was reached. Additionally, 11 patients died from leukemia progression, 4 had refractory disease, and 3 had follow-up loss. The median follow-up time was 697 days (range, 12-2,270). The 3-year cumulative incidence of relapse was 49.3 %. The probabilities of disease-free survival and overall survival at 3 years were 46.1 and 43.1 %, respectively. The dose of DNR was 100 % of the target dose, and there were no additional specific toxicities. The results show that escalated doses of DNR in induction chemotherapy are similar with the standard dose in response and toxicities. Our study indicates that a more effective regimen or better chemotherapy agents are needed to improve the CR rate and prolong survival in Philadelphia-negative adult ALL.
URI
http://hdl.handle.net/YU.REPOSITORY/29220http://dx.doi.org/10.1007/s00277-013-1728-y
ISSN
0939-5555
Appears in Collections:
의과대학 > 내과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE